Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • Telemedicine BW
    • MDR & IVDR

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Expert interview - 08/03/2023 Portrait photo of an older man with glasses and grey hair in a suit.

    How do new active substances from university research reach patients?

    Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-do-new-active-substances-university-research-reach-patients
  • Press release - 29/11/2022

    Prototype funding for two Konstanz projects

    Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
  • Press release - 12/04/2022

    Technology transfer award for PCR rapid test device for infection diagnostics

    Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
  • Press release - 10/03/2022

    Innovation Day Upper Rhine provides cross-border knowledge transfer

    Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
  • Press release - 26/05/2021

    Memetis continues its path to become a technology leader in Shape Memory driven miniature valving – Fluid-o-Tech S.r.l. invests an undisclosed amount to support memetis’ growth and development

    The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/memetis-continues-its-path-become-technology-leader-shape-memory-driven-miniature-valving-fluid-o-tech-srl-invests-undisclosed-a
  • Press release - 13/04/2021

    Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region

    Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
  • Press release - 04/03/2021

    CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
  • Company profile - 16/12/2019 Ausschnitt aus dem Mikrofluidik-System von Velabs, das dicht gepackt ist mit einzelnen Tröpfchen

    Velabs Therapeutics GmbH: each droplet is a test system

    Using microfluidics to detect new therapeutic antibodies is, in simple terms, the concept developed by Velabs Therapeutics GmbH. The Heidelberg-based start-up was spun out from the European Molecular Biology Laboratory (EMBL) in 2017 with the support of EMBLEM Technology Transfer GmbH. More recently, investors have provided the young company with additional funding to expand its technologies and applications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/velabs-therapeutics-gmbh-each-droplet-test-system
  • Press release - 27/06/2019

    Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme

    Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/velabs-therapeutics-announces-eur3-million-series-b-financing-advance-its-functional-antibody-screening-programme
  • Article - 15/01/2018 Schematic showing how a blockchain works.

    Blockchain technology as an opportunity for more transparency and self-determination

    In the healthcare sector, blockchain technology is still in the early stages of development, although it has huge potential in this field. It is expected that patients will particularly benefit from the introduction of a decentralised database for managing and sharing health-related information with treating physicians. Statutory health insurance companies become less important as intermediaries. But how exactly does this technology work?

    https://www.gesundheitsindustrie-bw.de/en/article/news/blockchain-technology-as-an-opportunity-for-more-transparency-and-self-determination
  • Article - 24/07/2017 The figure shows a model of the IDH1 complex. Two polypeptide chains (brown and light blue) form a dimer between which the substance BAY 1436032 (yellow) binds.

    Cancer medicine development as a science and industry partnership

    The German Cancer Research Center (DKFZ) and Bayer AG are collaborating on a strategic partnership focusing on the development of innovative cancer therapies. The two partners have developed an active substance which selectively blocks a mutation of a metabolic enzyme that occurs in certain types of cancer. The substance has been successfully tested in preclinical studies and is now also being tested in a clinical trial on patients with brain…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-medicine-development-as-a-science-and-industry-partnership
  • Article - 01/06/2017 Woman in a blue lab coat pipetting a blue liquid into an electrophoresis system.

    Biotechnology – key technology of the 21st century

    According to a study published by the German National Academy of Science and Engineering (acatech) on 5th April, biotechnology is a key technology of the 21st century and has huge innovation potential. What are the trends within the industry and what are the challenges we face?

    https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnology-key-technology-of-the-21st-century
  • Article - 19/04/2017 View of a laboratory work place with a broad range of laboratory utensils in which a person (on the left, wearing a white lab coat) is working with frozen samples.

    Are start-ups a matter for the boss? A professor’s thoughts on university spin-offs

    Research work and entrepreneurship are by no means mutually exclusive. There are numerous successful university spin-offs in the life sciences sector that prove this only too well. However, the road from a good idea to a commercially successful company can be long and arduous. Those who benefit from the support of their boss from the outset can consider themselves extremely fortunate. Prof. Dr. Hans-Georg Rammensee talks about his experience with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/are-start-ups-a-matter-for-the-boss-a-professors-thoughts-on-university-spin-offs
  • Press release - 24/01/2017

    Cancer Medications Learn to Hide

    The European Research Council awards Wilfried Weber an ERC Proof of Concept Grant. Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project “Hide and Seek with Cancer Drugs” in which he is working to improve the drugs used in cancer treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-medications-learn-to-hide
  • Press release - 13/12/2016 A laboratory device being loaded with small reaction vessels.

    Early-diagnosis systems from Baden-Württemberg help prevent the spread of drug-resistant pathogens

    More and more bacteria are developing resistance to multiple antimicrobial drugs. These multidrug-resistant bacteria can impede the action of common antibiotics via mutations or DNA transfer. More than 30,000 people are infected every year with multidrug-resistant bacteria in German hospitals alone. This could be prevented with appropriate hygiene measures and innovative test systems. Innovative test systems that enable reliable and rapid…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fruehdiagnostik-aus-baden-wuerttemberg-hilft-resistente-erreger-zu-stoppen
  • Article - 06/06/2016 Labbild_4.jpg

    ZEISS Vision Science Lab: understanding vision

    Carl Zeiss AG and the University of Tübingen have been jointly running the ZEISS Vision Science Lab since 2013. This is a workgroup that is both fully integrated into research as well as delivering results for the development and improvement of products. The “Industry on Campus” professorship shows how different interests can turn out successfully for both parties involved.

    https://www.gesundheitsindustrie-bw.de/en/article/news/zeiss-vision-science-lab-understanding-vision
  • Medical technology - 14/03/2016 Experimenteller_Interventionsraum_mit_mobilen_Rontgengerat_Monitoren_und_OP-Tisch_an_dem_der_Interventionsassistent_herangefahren_werden_kann.jpg

    The operating room of the future: minimally invasive and future-oriented intervention techniques

    Being able to diagnose and treat tumour patients in just a few hours is just one of the many promising goals of the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB). The overall goal of the Intervention and Therapy research group is to take innovative technologies for diagnostic and therapeutic interventions from laboratory development to prototype production for use in clinical trials.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-operating-room-of-the-future-minimally-invasive-and-future-oriented-intervention-techniques
  • The Baden-Württemberg healthcare industry

    Infrastructure

    Baden-Württemberg is home to numerous technology parks and thus offers an excellent infrastructure and attractive high-tech locations for life sciences companies in close proximity to scientific excellence. Young companies and business start-ups particularly stand to benefit from the opportunities for cooperation with other companies and research institutions in the technology parks and also from the relatively cheap rents for office and…

    https://www.gesundheitsindustrie-bw.de/en/location/infrastructure
  • Press release - 03/08/2012 09262_de.jpg

    Rentschler and MHH sign licensing agreement for a gene therapy vector system

    The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-and-mhh-sign-licensing-agreement-for-a-gene-therapy-vector-system
  • Press release - 12/07/2012

    7. Framework Programme: aid for organizations and companies

    The last round of file ideas for projects within the 7th Research framework program has been started. The European Commission will support innovative projects over eight billion euros to europe for global competition to strengthen and protect jobs. In addition to innovation, the focus is on health, environment, urbanization and waste disposal. The promotion is organizations and companies in all EU-member-states and partner countries open.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/7-framework-programme-aid-for-organizations-and-companies
  • Press release - 05/12/2011 10163_de.JPG

    Cellzome founder wins EU women innovators award

    Cellzome announces 5 December 2011 that Dr. Gitte Neubauer has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome. The prize value of 100.000 euros awarded by the European Commission Innovation Union was presented by Jos Manuel Barroso in a ceremony as part of the Innovation Convention 2011 in…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellzome-founder-wins-eu-women-innovators-award
  • Press release - 16/09/2011

    Five countries and EMBL sign Memorandum of Understanding to make ELIXIR a reality

    Today marks an important step for ELIXIR, Europe’s emerging research infrastructure for life-science information, as five countries plus the European Molecular Biology Laboratory (EMBL) have signed a Memorandum of Understanding to catalyse the implementation and construction of ELIXIR. The memorandum has been signed by Denmark, Finland, the Netherlands, Sweden and the United Kingdom, and more countries are planning to join in the near future. All…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-countries-and-embl-sign-memorandum-of-understanding-to-make-elixir-a-reality
  • Press release - 02/09/2011 15267_de.jpg

    German Government starts the initiative "Health - Made in Germany"

    The overall aim of the initiative is to exploit the dormant capacities that lie within the export of health care products made in Germany. In Germany, many companies are already world leaders in their fields, in part due to a policy of consistent and early promotion of health care in Germany. German technology suppliers possess decades of valuable experience in realizing health care projects both at home and abroad. Provider of products and…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-government-starts-the-initiative-health-made-in-germany
  • Press release - 27/06/2011 14614_de.jpg

    NMI TT GmbH – creating value from research

    NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-gmbh-creating-value-from-research
  • Article - 06/06/2011 Professor Gunter Voigt lectures and researches at HTWG Konstanz

    Knowledge transfer depends on the application of learning

    The ability of scientists from different disciplines to understand each other as well as excellent communication skills play an ever-increasing role in the transfer of knowledge from academic research to industry. Vice president of research at the Konstanz University of Applied Sciences HTWG Professor Gunter Voigt explains how academia and industry work together and also highlights the conditions that are necessary for such cooperations to lead…

    https://www.gesundheitsindustrie-bw.de/en/article/news/knowledge-transfer-depends-on-the-application-of-learning
  • Article - 30/05/2011 12064_de.jpg

    BioRN Innovation Center: Innovation broker for market and society

    With the establishment of the BioRN Innovation Center in the Rhine-Neckar Life Science Cluster, a professional, specialist and neutral intermediary between science and industry will be available to support the transfer of technologies in all of the cluster’s research institutions. In addition, the BioRN Innovation Center acts as a partner for strategic alliances set up to reinforce the competitiveness of the institutions on the European and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/biorn-innovation-center-innovation-broker-for-market-and-society
  • Article - 30/05/2011 14430_de.jpg

    Technology Licensing Office (TLB): invention and patent management

    The Technology Licensing Office TLB works in partnership with science and industry and is continuously coming up with new ways to ensure the economic success of inventions from all the key fields of technology. Dr. Frank Schlotter head of Life Sciences at the Karlsruhe-based TLB provides insights into the work that his office does taking as examples innovations from the fields of regenerative medicine and diagnostics.

    https://www.gesundheitsindustrie-bw.de/en/article/news/technology-licensing-office-tlb-invention-and-patent-management
  • Article - 30/05/2011 The photo shows nine men and women standing in two rows.

    CorTec GmbH – a bridge between ideas and action

    Brain machine interfaces that are able to read a paralysed patients desired movement from his or her brain and convert it into actual movement might be available in a few years time if everything goes to plan. CorTec GmbH a spin-off company of the University of Freiburg has a technology platform that is able to measure and interpret a persons brain activity and drive muscles or artificial prostheses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cortec-gmbh-a-bridge-between-ideas-and-action
  • Dossier - 30/05/2011 13541_de.jpg

    Knowledge and technology transfer as a social responsibility

    Technology transfer that efficiently exploits the intellectual property created by publicly funded research is necessary in order to turn scientific discoveries into successful innovations that improve people’s quality of life and boost the economy. The efforts made to rapidly transfer research results from the laboratory into clinical application for the benefit of patients leads to new strategic partnerships and structures in the field of…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/knowledge-and-technology-transfer-as-a-social-responsibility
  • Article - 18/01/2011 City of Heidelberg – old town

    Innovation hotspots

    In December 2010, the German and Israeli Ministers of Economics, Rainer Brüderle and Binyamin Ben-Eliezer, jointly opened the German-Israeli Innovation Day. The motto of the annual conference organised by the German-Israeli Life Sciences Committee in Heidelberg was “New ideas for a healthier world”. The conference enabled German participants to expand and reinforce their contacts with Israeli companies based on the long-standing cooperation…

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-hotspots
  • Article - 03/12/2010 The photo shows Dr. Bernd Dallmann welcoming the audience to the Science meets Business Day in the Freiburg Concert Hall.

    Review: Science meets Business Day 2010 (part I)

    Germinating seeds biosensors in the human body deaf people learning to hear again and new approaches to combat the flu virus the lectures held at the Science meets Business Day which concluded this years BioValley Science Week once again highlighted the innovations brought about through the joint efforts of research and industrial players on the Upper Rhine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-i
  • Press release - 16/11/2010 11459_de.jpg

    Summit conference on regional development in the Rhine-Neckar Metropolitan Region

    To learn from leading regional developers this was the goal set by the representatives of the Biotechnology Cluster Rhine-Neckar BioRN for the Regional Development Summit. Representatives from business science and politics in the Rhine-Neckar Metropolitan Region met in the Villa Bosch in Heidelberg on November 11 with experts from the leading international high-tech sites in Leuven Belgium Cambridge UK and Israel.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/summit-conference-on-regional-development-in-the-rhine-neckar-metropolitan-region
  • Article - 20/09/2010 The photo shows a pipetting system above a multi-well cell culture plate placed on the microscope stage.<br /> <br />

    PROcellcare – a cell nanny enters the market

    The idea and the first laboratory device were developed in Heidelberg at the European Molecular Biology Laboratory EMBL one of the worlds top-class research institutions before being turned into a product by the Heiligkreuzsteinach-based company PROdesign. PROcellcare a fully automated cell analysis and nutrient supply system that can be integrated into microscope is an impressive demonstration that innovation very much depends on the right…

    https://www.gesundheitsindustrie-bw.de/en/article/news/procellcare-a-cell-nanny-enters-the-market
  • Press release - 09/09/2010

    Jiangnan University, Wuxi

    Jiangnan University JU is one of Chinas key universities of the 211 Project and functions under the Ministry of Education. The university host the National Engineering Laboratory of Fermentation Technology the Key Laboratory of Industrial Biotechnology the Engineering Research Center of Bioactive Product Processing Jiangsu Province and the Collection of Industrial Microbes Resources.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/jiangnan-university-wuxi
  • Press release - 23/06/2010 two buildings with lines of trees in front

    Technology park „bioBAY“ - life science infrastructure the Chinese way

    Being one of Baden-Württemberg’s global partner regions, the Chinese province of Jiangsu deserves special attention in the field of life sciences. The highly dynamic bioBAY park located in the city of Suzhou puts a strong emphasis on bio- and nanotechnologies. With its numerous science and business opportunities bioBAY has a lot to offer also to potential partners from Baden-Württemberg.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-park-biobay-life-science-infrastructure-the-chinese-way
  • Article - 03/05/2010 11264_de.jpg

    In order to innovate, we must come down from the ivory tower

    At talks given at the recent Biotechnology Days in Berlin representatives of a number of different BMBF-funded clusters showed that numerous strategies to enable the industrial production of biopolymers and biomaterials from resources other than oil are now available.

    https://www.gesundheitsindustrie-bw.de/en/article/news/in-order-to-innovate-we-must-come-down-from-the-ivory-tower
  • Article - 18/03/2010 The photo shows a Y-shaped molecule. The major branch is shown in red and the other two in yellow.<br />

    Cancer treatment adapted to individual patient requirements

    There is still no treatment available for a number of non-Hodgkin B-cell lymphomas. Chemotherapy, which is the standard method of treating the lymphomas, has unpleasant side effects. Researchers led by Prof. Dr. Hendrik Veelken at the Freiburg University Medical Centre in cooperation with Freiburg-based CellGenix Technologie Transfer GmbH have developed a promising new treatment strategy. Results of the Phase I and the Phase II study, which has…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-treatment-adapted-to-individual-patient-requirements
  • Press release - 11/02/2010 10146_de.jpg

    BioValley receives funding package

    BioValley the cross-border life sciences cluster in the border area between Germany France and Switzerland has put in place new measures to support the regional economy and science. The European Union will provide funding through the INTERREG IV programme.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biovalley-receives-funding-package
  • Press release - 11/11/2009 10061_de.jpg

    Hematopoietic stem cell treatment with a new gene therapy vector: A first success treating a brain disease

    Two children with adrenoleukodystrophy (ALD), a fatal brain disease, have been successfully treated with a new gene therapy vector. Two years after treatment, the disease evolution has been stopped, and no adverse effect of the gene therapy has been observed so far. The results of this clinical trial conducted by Drs Nathalie Cartier and Patrick Aubourg (Inserm, France) in collaboration with European partners have just been published in Science…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hematopoietic-stem-cell-treatment-with-a-new-gene-therapy-vector-a-first-success-treating-a-brain-di
  • Press release - 09/10/2009 09781_de.jpg

    BIOTECHNICA 2009 - turning ideas into value

    BIOTECHNICA 2009 which took place in Hanover Germany from 6th to 8th October 2009 featured the seminal motto Turning ideas into value. The exhibition programme was rounded off by numerous talks and plenary discussions held at the joint Baden-Württemberg booth.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnica-2009-turning-ideas-into-value
  • Press release - 18/09/2009 09634_de.jpg

    BioRegio STERN initiates cooperation with French medtech network

    The STERN BioRegion and Ple Technologique de Haute-Champagne are looking to promote cooperation between French and German companies and research institutes in the medtech and associated sectors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bioregio-stern-initiates-cooperation-with-french-medtech-network
  • Press release - 30/07/2009

    INTERREG funding for innovations

    The INTEREG IV B programmes are financial instruments of the European Union designed to support the European-wide cooperation between small- and medium-sized companies, research institutions and government authorities. A meeting held on 22nd July 2009 in Heilbronn provided special information on the programme, with a special focus on the cooperation between North-West and Central Europe.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/interreg-funding-for-innovations
  • Press release - 17/07/2009

    Investigation of living cellular complexes with the fastest nano light microscope in the world

    Prof. Dr. Dr. Christoph Cremer of the Kirchhoff Institute of Physics at the University of Heidelberg and his team have developed a high-performance microscope. This cutting edge microscope enables scientists to investigate molecular details of several cells simultaneously using standard fluorescent dyes such as green fluorescent protein (GFP). The world’s fastest nano light microscope uses a new localisation microscope method known as spectral…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/investigation-of-living-cellular-complexes-with-the-fastest-nano-light-microscope-in-the-world
  • Article - 15/07/2009 The photo shows instruments in a laboratory

    The gap in the value creation chain

    On a national level the University of Freiburg comes out reasonably well in comparison with other universities regarding the number of patents filed and licensed. But is it enough to protect an intellectual property and sell it to a company? No says Prof. Dr. Bernhard Arnolds from the Central Office of Research Funding and Technology Transfer at the University of Freiburg.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-gap-in-the-value-creation-chain
  • Press release - 07/07/2009

    Investment in the future: ILM receives funds for the purchase of equipment

    The Ulm-based Institute for Laser Technologies in Medicine and Metrology (ILM) has received a 335,000 euro injection in 2009 through the German government’s Future Investment Programme (Economic Stimulus Packet II), according to the Baden-Württemberg Minister of Economic Affairs Ernst Pfister. The funds, 75 per cent of which are provided by the German government and 25 per cent by the state of Baden-Württemberg, will be used for the modernisation…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/investment-in-the-future-ilm-receives-funds-for-the-purchase-of-equipment
  • Article - 23/04/2009 08468_de.jpg

    Cancer therapy targets angiogenesis

    The idea of starving tumours by interrupting their blood supply has despite initial drawbacks generated the production of blockbuster drugs and is now a major RD focus for biotechnology and pharmaceutical companies. But the biological effects are more complicated than originally expected.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-therapy-targets-angiogenesis
  • Article - 16/09/2008

    New opportunities for the MedCare TechArea

    Although the MedCare TechArea was not one of the five top clusters to recently receive an award from the German Federal Ministry of Education and Research the cluster and its MedCare TechArea will be further developed.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-opportunities-for-the-medcare-techarea
  • Article - 10/08/2008

    Technology transfer through dialogue

    The new iNNOVATION fORUM of the Baden-Württemberg MicroMountains Network offered researchers and the medical device industry an intensive moderated dialogue and the chance to make new contacts and to improve their chances for future innovations.

    https://www.gesundheitsindustrie-bw.de/en/article/news/technology-transfer-through-dialogue
  • Article - 15/07/2008

    Politicians to appreciate the new experimental operating theatre

    The experimental operating theatre at the University Hospital in Tübingen is currently attracting nationwide attention. The simulation and testing laboratory was officially opened on the 14th July by Minister President Günther H. Oettinger.

    https://www.gesundheitsindustrie-bw.de/en/article/news/politicians-to-appreciate-the-new-experimental-operating-theatre
  • Article - 17/04/2008

    Targeted gene replacement in barley

    The GABI-PRECISE consortium which originates from the Genome Analysis of the Plant Biological System GABI initiative has announced a cooperative project on the introduction of gene targeting in barley.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeted-gene-replacement-in-barley

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search